Award
National Cancer Institute 5P50CA097190-19
Project 3: Determining biomarkers for responsiveness to immunotherapy targeting LAG3/PD1 in HNSCC
Recipient
University of Pittsburgh at Pittsburgh, Pittsburgh, PA, United States
Award Amount
$318,409.00
Ceiling
$318,409.00
Awarded
September 01, 2025
Identifier
5P50CA097190-19
Research funding awarded to University of Pittsburgh for immunotherapy studies targeting LAG3/PD1 in HNSCC, focusing on biomarker discovery and combination therapy development.
Description
This project aims to understand the mechanisms of action for immunotherapies targeting LAG3 and PD1, identify biomarkers of response, and develop combination therapies to improve outcomes for patients with head and neck squamous cell carcinoma (HNSCC).